araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 71-year-old female with lung cancer; genetic feature: ROS1

Clinical trial: Losartan in Treating Pulmonary Fibrosis in Patients With Stage I, II, or III Non-Small Cell Lung Cancer

Summary: RATIONALE: Losartan potassium may be effective in treating pulmonary fibrosis caused by radiation therapy in patients with non-small cell lung cancer.
  PURPOSE: This clinical trial is studying losartan to see how well it works in treating pulmonary fibrosis caused by radiation therapy in patients with stage I, stage II, or stage III non-small cell lung cancer.

Detailed description: OBJECTIVES:
  Primary
  -  To evaluate the effects of losartan potassium on the disease progression in patients with stage I-III non-small cell lung cancer and radiation-induced pulmonary fibrosis.
  -  To determine the feasibility of losartan potassium as a possible treatment for radiation-induced pulmonary fibrosis.
  Secondary
  -  The evaluate the effects of losartan potassium on the degree of dyspnea, and lung function (FEV_1 and FVC) in these patients.
  OUTLINE: This is a multicenter study.
  Patients receive oral losartan potassium once daily for 6 months in the absence of disease progression or unacceptable toxicity.
  Patients undergo assessment of pulmonary function (e.g., gas movement, lung capacity, and diffusion of gases) by spirometry and dyspnea by the Visual Analog Scale (VAS) at baseline and at weeks 12 and 24.

Eligibility: INCLUSION CRITERIA:
  -  At least 18 years of age or older
  -  Diagnosed with non-small cell lung cancer stage I, II, IIIa, or IIIb
  -  Diagnosis of radiation-induced pulmonary fibrosis (as defined by National Cancer Institute's Common Terminology Criteria for Adverse Events [CTCAE] V3.0 Grade I to Grade III) and within 2 years of the last radiation therapy treatment
  EXCLUSION CRITERIA:
  -  Patients with a pneumonectomy
  -  Allergy or allergic reaction to Losartan or any other angiotensin II receptor blocker
  -  Use of an angiotensin II receptor blocker currently or within 6 months of study entry which include: losartan, valsartan, irbesartan, candesartan, cilexetil, eprosartan mesylate, and telmisartan
  -  Bilateral renal artery stenosis, hereditary or idiopathic angioedema, or uncontrolled hypotension
  -  Patients taking lithium
  -  Currently smoking or smoked within 6 months of study entry
  -  Pregnant, intending to become pregnant or breastfeeding
  -  Baseline systolic blood pressure < 100 mmHg
  -  History of lung transplant
  -  History of kidney failure or liver disease
  -  Inability to attend clinic visits

Relevance to patient case: not relevant
Patient case: 71-year-old female with lung cancer; genetic feature: ROS1

Clinical trial: Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer

Summary: RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
  PURPOSE: This laboratory study is looking at tumor tissue samples and blood samples to learn more about DNA changes in patients with lung cancer.

Detailed description: OBJECTIVES:
  -  Examine the mutational status of the EGFR pathway in tumor and blood samples from patients with lung cancer.
  -  Correlate the EGFR pathway mutations in these samples with clinical outcomes of these patients.
  OUTLINE: Archived tumor tissue and blood samples are analyzed via PCR to detect EGFR pathway mutations in DNA.

Eligibility: DISEASE CHARACTERISTICS:
  -  Histologically or cytologically confirmed lung cancer
  PATIENT CHARACTERISTICS:
  -  Not specified
  PRIOR CONCURRENT THERAPY:
  -  May have received prior EGFR inhibitors

Relevance to patient case: not relevant
Patient case: 71-year-old female with lung cancer; genetic feature: ROS1

Clinical trial: Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer. ICORG 07-12

Summary: RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in peptides and proteins and identify biomarkers related to cancer.
  PURPOSE: This research study is looking at blood samples from patients with malignant melanoma, metastatic breast cancer, advanced lung cancer, pancreatic cancer, or colorectal cancer.

Detailed description: OBJECTIVES:
  Primary
  -  To assess which potential peptide and protein markers produced by human melanoma, lung, breast, pancreatic, and colorectal cell lines may be detectable in serum of patients from these five disease groups.
  Secondary
  -  To conduct further extensive investigation with respect to identification of the protein/peptide involved, determination of specificity for each cancer, and development of more sensitive assays to look for such markers in a wider population of patients, including those undergoing therapy.
  OUTLINE: This is a multicenter study.
  Blood samples are collected before surgical intervention or treatment to assess peptide and protein markers.

Eligibility: DISEASE CHARACTERISTICS:
  -  Diagnosis of 1 of the following advanced metastatic malignancies:
  -  Malignant melanoma
  -  Lung cancer
  -  Breast cancer
  -  Pancreatic carcinoma
  -  Colorectal cancer
  -  Advanced and/or metastatic disease
  -  Hormone receptor status not specified
  PATIENT CHARACTERISTICS:
  -  Menopausal status not specified
  PRIOR CONCURRENT THERAPY:
  -  Not specified

Relevance to patient case: not relevant
Patient case: 71-year-old female with lung cancer; genetic feature: ROS1

Clinical trial: Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer

Summary: Phase II, randomised, controlled, non comparative study with 2 parallel groups:
  -  Arm A: patients will receive induction chemotherapy (cisplatin and docetaxel) followed by a concomitant radio-chemotherapy including 2 cycles of cisplatin and vinorelbine associated with a weekly cetuximab infusion during the radiotherapy.
  -  Arm B: patients will receive induction chemotherapy (cisplatin and docetaxel) followed by a concomitant radio-chemothérapy including 2 cycles of cisplatin and etoposide associated with a weekly cetuximab infusion during the radiotherapy.


Eligibility: Inclusion Criteria:
  -  Non-Small-Cell Lung cancer cytologically or histologically proved
  -  Stage III AN2 inoperable or non resectable
  -  presence of at least one one dimension measurable target (at least 10 mm with spiral tomodensitometry)
  -  Possibility to include all targets in one irradiation field
  -  Age of 18 to 70
  -  Patients non previously treated
  -  Performance Status 0 or 1
  -  Loss of weight ≤10% in the 3 last months
  -  Neutrophil ≥ 1500/mm3 and platelets ≥ 100000/mm3
  -  Creatinine clearance ≥ 60 ml/min
  -  total bilirubin ≤ 1,5N and ASAT ALAT ≤ 2,5N
  -  Respiratory function normal: VEMS ≥ 40% theorical, DLCO/VA ≥ 50% theorical and PaO2 ≥ 60 mmHg
  -  Signed inform consent form
  -  Compliance to radiotherapy 66 Gy with dosimetry V20 ≤ 35% and pulmonary mean dose≤20 Gy
  Exclusion Criteria:
  -  Pretreated bronchial carcinoma, excepted endoscopic deobstruction
  -  operable bronchial carcinoma
  -  small cell lung cancer, composite cancer, neuroendocrine cancer, broncho alveolar cancer
  -  superior vena cava syndroms
  -  puncturable pleural effusion
  -  metastatic lung cancer
  -  Stage IIIb cancer with neoplastic pericarditis
  -  Previous thoracic irradiation
  -  severe cardiac disease in the 12 months before inclusion
  -  interstitial lung disease
  -  anti-EGFR and anti-VEGF treatments
  -  hypersensitivity to murine proteins and allergies to protocol drugs
  -  uncontrolled infectious state
  -  HIV patient
  -  corticoid definitive contraindication
  -  péripheric neuropathy grade≥2
  -  neurologic, psychiatric and organic disorder
  -  past or concomitant cancer excepted treated skin baso-cellular cancer or in situ cervical cancer, or any cancer only surgically treated for 5 years
  -  breastfeeding woman

Relevance to patient case: not relevant
Patient case: 71-year-old female with lung cancer; genetic feature: ROS1

Clinical trial: An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer

Summary: This study will evaluate the anti-tumour activity, safety and tolerability of RO4929097 as monotherapy in patients with recurrent or refractory non-small cell lung cancer. Patients will receive oral doses of RO4929097 of 80mg (cohort 1) or recommended Phase II dose (cohort 2) on a 3 days on 4 days off schedule. Anticipated time on study treatment is until disease progression or unacceptable toxicity. Target sample size is <50.


Eligibility: Inclusion Criteria:
  -  adult patients, >/= 18 years of age
  -  stage IIIB/IV recurrent or refractory non-small cell lung cancer
  -  at most 2 lines of prior therapy in the metastatic setting (first line: platinum containing regimen and bevacizumab; second line: EGFR-targeted therapy)
  -  ECOG performance status 0-2
  -  adequate liver, renal and bone marrow function
  Exclusion Criteria:
  -  prior chemotherapy or radiotherapy </= 4 weeks before first dose of study drug
  -  history of other malignancy within the past 2 years, except for basal cell skin carcinoma or in situ cervical carcinoma
  -  history of CNS metastases or leptomeningeal metastases, except for clinically stable disease
  -  serious cardiovascular illness

Relevance to patient case: not relevant
Patient case: 71-year-old female with lung cancer; genetic feature: ROS1

Clinical trial: Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours

Summary: This study is being conducted to assess the safety, tolerability and PK of AZD1480 in patients with advanced solid malignancies.


Eligibility: Inclusion Criteria:
  -  Patients with advanced solid cancer without available therapy in the escalation phase and mutation positive NSCLC or non-smokers with other primary tumors lung metastasis in the expansion phase
  -  ECOG Performance Status 0-1
  -  Evidence of post-menopausal status in females or males willing to use barrier contraception
  Exclusion Criteria:
  -  Prior therapy with any JAK2 medications
  -  Significant lung disorder or lung disease. Previous radiation therapy to chest wall or chest infection requiring antibiotic treatment within 21 days before study screening. Evidence of significant pulmonary hypertension or COPD
  -  Eye disease of the cornea

Relevance to patient case: not relevant
Patient case: 71-year-old female with lung cancer; genetic feature: ROS1

Clinical trial: An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Summary: This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.


Eligibility: Inclusion Criteria:
  -  histologically or cytologically proven diagnosis of malignancy other than NSCLC
  -  positive for translocation or inversion event involving the ALK gene locus
  -  positive for ALK amplification events
  -  positive for ALK activating point mutations
  Exclusion Criteria:
  -  mutations of amplifications involving the c-Met gene but not the ALK gene
  -  concurrent treatment on another therapeutic clinical trial
  -  prior therapy specifically directed against ALK

Relevance to patient case: not relevant
Patient case: 71-year-old female with lung cancer; genetic feature: ROS1

Clinical trial: A Retrospective Pharmacoeconomic Study of Lung Cancer

Summary: Lung cancer is the No. cause of cancer death in Taiwan. Yet most of lung cancer are diagnosed at late stage, not amenable to surgical resection. With the introduction of new targeted agents, such as EGFR tyrosine kinase inhibitors and the identification of EGFR mutations, lung cancer management has markedly changed in recent years. However, these new agents are costly and their payment is restricted in certain situations defined National Insurance Agency. Therefore, using databases from National Insurance Agency might not be able to reflect the exact impact on pharmacoeconomics. In this study, the investigators will analyze the data from a tertiary medical center, where all the costs including insurance reimbursement, co-payment, and payment not covered by insurance. The investigators will also compare with the investigators results with national database to analyze the cost benefit of these new agents on lung cancer.


Eligibility: Inclusion Criteria:
  -  lung cancer patients in WanFang Hospital
  Exclusion Criteria:
  -  non

Relevance to patient case: not relevant
Patient case: 71-year-old female with lung cancer; genetic feature: ROS1

Clinical trial: A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

Summary: This study will evaluate the anti-cancer effects of crizotinib when compared with standard chemotherapy in patients with ALK positive lung cancer.


Eligibility: Inclusion Criteria:
  -  Proven diagnosis of locally advanced not suitable for local treatment, recurrent and metastatic non-squamous cell carcinoma of the lung
  -  Positive for translocation or inversion events involving the ALK gene locus
  -  No prior systemic treatment for locally advanced or metastatic disease; Patients with brain metastases only if treated and neurologically stable with no ongoing requirement for corticosteroids
  -  Evidence of a personally signed and dated informed consent document and willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures including completion of patient reported outcome [PRO] measures.
  -  18 years of age or older with the exception of India which has an upper age limit of 65 years old
  Exclusion Criteria:
  -  Current treatment on another therapeutic clinical trial.
  -  Prior therapy directly targeting ALK.
  -  Any of the following within the 3 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack. - - Appropriate treatment with anticoagulants is permitted.
  -  Ongoing cardiac dysrhythmias of NCI CTCAE Grade >=2, uncontrolled atrial fibrillation of any grade, or QTc interval >470 msec.
  -  Pregnancy or breastfeeding.
  -  Use of drugs or foods that are known potent CYP3A4 inducers/inhibitors Concurrent use of drugs that are CYP3A4 substrates with narrow therapeutic indices.
  -  Known HIV infection
  -  Known interstitial lung disease or interstitial fibrosis
  -  Other severe acute or chronic medical conditions (including severe gastrointestinal conditions such as diarrhea or ulcer) or psychiatric conditions, or laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration, and which would, therefore, make the patient inappropriate for entry into this study

Relevance to patient case: not relevant
Patient case: 71-year-old female with lung cancer; genetic feature: ROS1

Clinical trial: Lung Inflammation and Lung Metastases From Breast Cancer

Summary: The purpose of this study is to find out if there is a link between cigarette smoking, inflammation and the spread of breast cancer to the lung. We think that women who are current or former smokers may be at increased risk for breast cancer spreading to the lung compared to women who have never smoked. Smoking causes inflammation in the lung in some women. Researchers at Memorial Sloan-Kettering (MSKCC) think that smoking-related lung inflammation may increase the chance of breast cancer spreading to the lung. In order to find out whether inflammation plays a role in breast cancer spreading to the lung, we will measure a urinary marker of lung inflammation. This will allow us to determine if this marker is more commonly elevated in women with breast cancer that has spread to the lung compared to those without breast cancer in the lung. We will also collect DNA from blood to have the opportunity to determine if there are differences in DNA in women with or without breast cancer that has spread to the other sites including the lung. We will also collect blood to determine if we can identify risk factors for the spread of breast cancer to the lungs.


Eligibility: Inclusion Criteria:
  -  Registered patient at MSKCC
  -  Histologically proven breast cancer. It is not necessary that pathology be reviewed at MSKCC
  -  Age ≥18 years Group 1 (A and B)
  -  Diagnosed with metastatic breast cancer on biopsy or imaging study.
  -  Patients will be considered to have lung metastases, and will be assigned to group 1A if any of the following criteria are met, otherwise patients will be assigned to group 1B "No known Lung Metastases," Biopsy-proven lung metastasis.
  -  Pleural effusion with cytologic evidence of malignancy.
  -  Pleural effusion, exudative in character, without alternative explanation and attributed, in the opinion of the clinician to metastatic disease.
  -  Symptoms attributable to lung metastases and a radiological pattern interpreted by a radiologist as suspicious for metastatic disease.
  -  Any pulmonary nodule on chest radiograph, CT scan, PET-CT or MRI, which is interpreted by the clinician and radiologist to be metastatic in etiology, whether or not a biopsy was performed, and regardless of symptoms.
  -  A radiographic pattern interpreted by a radiologist as consistent with lymphangitic carcinomatosis.
  Group 2 (Controls)
  -  History of early breast cancer and currently no evidence of disease
  Exclusion Criteria:
  -  Inability to provide written informed consent.
  -  Inability to complete smoking and NSAID questionnaire.
  -  Steroid use within the previous 4 weeks.
  -  Radiotherapy to the breast, chest wall or axilla within the previous 3 months.
  -  Men with breast cancer.

Relevance to patient case: not relevant
Patient case: 71-year-old female with lung cancer; genetic feature: ROS1

Clinical trial: Studies Examining the Importance of Smoking After Being Diagnosed With Lung Cancer

Summary: A large project consisting of:
  a) an observational trial where smoking status is recorded on 1400 consecutive people newly diagnosed with lung cancer. Smoking status is biologically validated with exhaled carbon monoxide (eCO) levels every 3 months. Survival, cancer progression and treatment complications will be recorded and compared in smokers, ex-smokers and never smokers.

Detailed description: Smoking causes around 85% of lung cancer. Continued smoking after diagnosis probably worsens survival and increases treatment complications but prospective well-designed studies are lacking.
  This project is an observational cohort study recording outcomes in smokers, never-smokers, and ex-smokers, using exhaled carbon monoxide to validate smoking status when they attend for further lung cancer clinics.
  This project is unique, as every patient with a clinical diagnosis of lung cancer will have their smoking status biologically validated by a quick and easy test, and those enrolled in the smoking cessation treatments or not will also complete a generic quality of life questionnaire at regular intervals. These appointments will coincide with other hospital appointments wherever possible, and survival status will reported up to 24 months after enrolment.

Eligibility: Inclusion Criteria:
  -  clinical diagnosis of lung cancer
  Exclusion Criteria:
  -  refusal Consent
  -  inability to provide exhaled CO
  -  active psychiatric illness or substance misuse
  -  concurrent malignancies of another type other than non-melanoma skin cancer
  -  unable to travel for sessions with smoking cessation counsellor and / or outpatient visits from outset
  -  WHO performance status 4
  -  Life expectancy less than 6 weeks.

Relevance to patient case: not relevant
Patient case: 71-year-old female with lung cancer; genetic feature: ROS1

Clinical trial: A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.

Summary: This is Phase I, open-label and dose escalation study to evaluate the safety and tolerability of AZD1480(JAK2 inhibitor) in Asian patients with advanced solid tumors (Part A and C) and in patients with advanced HCC (Part B) in the escalation phase, EGFR or ROS mutant NSCLC and non-smokers with lung metastasis and gastric cancer in the expansion phase and to evaluate daily and BID dosing.


Eligibility: Inclusion Criteria:
  -  Male or female aged 18 years or older
  -  For Part A and C: Histological or cytological confirmation of a solid malignant tumour refractory to standard therapies or for which no standard therapies exist. Patients with lymphoma & HCC are excluded.
  -  For Expansion : Histological or cytological confirmation of
  -  Expansion 1: EGFR and/or ROS mutant NSCLC or Non-smokers with lung metastasis
  -  Expansion 2: Gastric cancer or solid tumour with biopsy available (consenting paired biopsies)refractory to standard therapies or for which no standard therapies exist. Patients with lymphoma & HCC are excluded.
  -  For Part B : Advanced or metastatic HCC, unresectable and incurable with ablative therapy or TACE, with no standard therapy available.
  -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1 with no deterioration over the previous 2 weeks
  -  For Part B : Child-Pugh liver function status classified as A to B7
  Exclusion Criteria:
  -  For any other chemotherapy, immunotherapy or anticancer agents, within 5 half lives or 3 weeks must have elapsed from treatment to of the first dose of investigational product, whichever is shorter.
  -  With the exception of alopecia, any unresolved toxicities from prior therapy ≥ Grade 2 of CTCAE V4.02 at the time of starting study (except LFTs for HCC patients, which may be Grade 2 at the time of starting the study)
  -  Any of the following conditions:Interferon treatment for HBV and HCV Prior Liver Transplantation
  -  Inadequate bone marrow reserve or organ function as demonstrated by laboratory values
  -  Evidence of established interstitial lung disease(ILD) on baseline high resolution computerized tomography(HRCT)

Relevance to patient case: not relevant
Patient case: 71-year-old female with lung cancer; genetic feature: ROS1

Clinical trial: GWAS Research of Lung Cancer in Tianjin

Summary: To study the association of Genetic Polymorphisms with Lung Cancer Risk in Tianjin Population.

Detailed description: Eligibility criteria:
  -  nonsmoker
  -  female
  -  age between 35 and 80
  -  no other types of tumors history
  -  frequency-matched cases and controls on gender and age
  Outcome measures:
  -  OR(odds ratio)
  -  RR(risk ratio)
  -  CI(confidence interval)
  -  SAS software

Eligibility: Inclusion Criteria:
  -  Non-small cell lung cancer
  -  Age from 35 to 80 years old
  -  Female
  -  Non-smokers
  -  Frequency-matched on age and gender
  Exclusion Criteria:
  -  Previous medical history of cancer
  -  Previous radiotherapy
  -  Previous chemotherapy

Relevance to patient case: not relevant